BIAF: bioAffinity Technologies Inc. Price-to-Revenue Ratio

Symbol and logo of brand bioAffinity (BIAF)

The market capitalization-to-revenue ratio for bioAffinity Technologies (BIAF) demonstrates volatility, where the value of 0.80 corresponds to the current metric, correlating with geopolitical barriers in test exports. Business stability is based on the integration of non-invasive diagnostics into government protocols, ensuring the sale of reagents. The efficiency of the operating model is complemented by a streamlined express delivery system for kits to clinics, eliminating supply chain disruptions.

bioAffinity Technologies (BIAF): Price-to-Revenue Ratio from 05/28/2023 to 11/13/2026

Analytical breakdowns for bioAffinity Technologies (BIAF)

- share price and consensus valuation forecast:
Price Performance Chart bioaffinitytech.com|BIAF - Analyst Consensus Forecast
- market capitalization information:
Market Value bioAffinity|BIAF - Enterprise Value
- issuer book value statistics:
Net Assets per Share bioAffinity Technologies|BIAF - Company Book Value|Market-to-Book Ratio bioaffinitytech.com|BIAF - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital bioAffinity Technologies|BIAF - Long-Term Debt to Capital|Current Liabilities to Equity bioaffinitytech.com|BIAF - Company Aggregate Debts|Debts to Book Capitalization Ratio bioAffinity|BIAF - Company Long-Term Debts|Short-Term Debt Volume bioAffinity Technologies|Immediate Liquidity Ratio bioaffinitytech.com
- net income and valuation ratios data:
BIAF - Net Profit|Company Profit Forecast bioAffinity Technologies|BIAF - Price to Earnings Ratio|Market Cap to Future Earnings Ratio bioaffinitytech.com|BIAF - Price/Earnings to Growth Multiple|Company Value to EBITDA bioAffinity|BIAF - Operating profit before deduction of amortization|Earnings per share for the trailing year bioAffinity Technologies|BIAF - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months bioaffinitytech.com|BIAF - Earnings growth in current year|Expected net earnings per share growth next year bioAffinity Technologies
- total revenue and sales volume data:
BIAF - Revenue and Sales Volume|Company Future Sales Volume bioaffinitytech.com|BIAF - P/S Multiple|Forward Price to Sales bioAffinity
General company analysis:bioAffinity Technologies Inc. - BIAF
Signature product of bioAffinity Technologies

Investors are assessing the potential of bioAffinity Technologies (BIAF) through the ratio of market capitalization to annual revenue, which determines the value of each dollar of sales. By analyzing the price/sales multiple of bioAffinity Technologies (BIAF), one can understand to what extent the market is pricing in the success of non-invasive lung cancer screening for high-risk groups. Low indicator values coupled with stagnant margins may signal a value trap, neutralizing the attractiveness of scaling the TAM.

Competing companies

AVBP (ArriVent BioPharma, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple LTRN (Lantern Pharma)|eEFFECTOR Therapeutics, Inc. - Price-to-Revenue Ratio